Open-Label Study of Setmelanotide in Hypothalamic Obesity
Status:
Recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the percent change in body weight in response to
setmelanotide administered subcutaneously (SC) daily in obese subjects with hypothalamic
obesity (HO).